

H. Lundbeck A/S

Ottiliavej 9
DK-2500 Valby, Copenhagen
CVR number: 56759913
LEI code: 5493006R4KC2OI5D3470

Tel +45 36 30 13 11
Fax +45 36 43 82 62

E-mail info@lundbeck.com
www.lundbeck.com



Corporate Release

Lundbeck increases its share capital by 5,631 shares (0.0028 % of outstanding shares) as a result of exercise of employee warrants

Valby, Denmark, 18 February 2019 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 28,155 as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 3,795 shares at DKK 121 and 1,836 shares at DKK 113. Proceeds to the company are DKK 666,663 (approximately USD 0.101 million). The increase corresponds to approximately 0.0028 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority.

Lundbeck's current share capital amounts to DKK 995,524,980. The capital increase is expected to be finalized shortly, and the total number of voting rights and the total share capital will after this capital increase be:

Number of shares (nominal value DKK 5)	Nominal value of shares (DKK)	Number of votes
199,110,627	995,553,135	199,110,627

Lundbeck contacts

Investors:

Palle Holm Olesen
Vicedirektør, Investor Relations
palo@lundbeck.com
+45 30 83 24 26

Media:

Mads Kronborg
Kommunikationschef
mavk@lundbeck.com
+45 36 43 40 00



About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at [@Lundbeck](https://twitter.com/Lundbeck) and via [LinkedIn](https://www.linkedin.com/company/lundbeck).

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made considering past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.